GSK has collaborated with the University of Birmingham (UoB) for many years across various areas such as dentistry, consumer healthcare, and respiratory research. The collaboration has expanded in recent years to include autoimmune disease research through GSK's Experimental Medicine Unit. One example of novel collaboration involved clinical academics and researchers from both organizations meeting with Sjogren's Syndrome patients to understand their experiences and insights that could aid drug development. Another example was the placement of a GSK-employed postdoctoral scientist at UoB for research on developing a model to explore potential Sjogren's syndrome drug candidates. The partnership allows both organizations to advance their work in complementary ways to improve global healthcare.
GSK has collaborated with the University of Birmingham (UoB) for many years across various areas such as dentistry, consumer healthcare, and respiratory research. The collaboration has expanded in recent years to include autoimmune disease research through GSK's Experimental Medicine Unit. One example of novel collaboration involved clinical academics and researchers from both organizations meeting with Sjogren's Syndrome patients to understand their experiences and insights that could aid drug development. Another example was the placement of a GSK-employed postdoctoral scientist at UoB for research on developing a model to explore potential Sjogren's syndrome drug candidates. The partnership allows both organizations to advance their work in complementary ways to improve global healthcare.
GSK has collaborated with the University of Birmingham (UoB) for many years across various areas such as dentistry, consumer healthcare, and respiratory research. The collaboration has expanded in recent years to include autoimmune disease research through GSK's Experimental Medicine Unit. One example of novel collaboration involved clinical academics and researchers from both organizations meeting with Sjogren's Syndrome patients to understand their experiences and insights that could aid drug development. Another example was the placement of a GSK-employed postdoctoral scientist at UoB for research on developing a model to explore potential Sjogren's syndrome drug candidates. The partnership allows both organizations to advance their work in complementary ways to improve global healthcare.
University of Birmingham (UoB) for many years across a variety of areas including dentistry, within the Consumer Healthcare business, and respiratory, within Pharmaceuticals. Interactions between the two organisations range from clinical academics providing advisory services, collaborative research to take drugs towards market, CASE studentships to undertake specific experimentation, and clinical trial activity for the final phases of testing of promising drug candidates.
In the past three years, the breadth of
collaborative activities has expanded, particularly in the area of autoimmune disease and in conjunction with GSK’s Experimental Medicine Unit. It is in this space that the most novel approaches to collaboration between GSK and Another example of where a novel approach UoB have arisen. One such example was where clinical academics from the to collaboration has been applied is the University came together with their appointment of a post-doctoral scientist, clinical and scientific collaborators from employed by GSK, who will work in the GSK to meet patients who had been laboratory at the University of Birmingham diagnosed with Sjogren’s Syndrome. This is for the first two years of their three year a long-term autoimmune condition that post, returning to GSK for the third year. affects parts of the body that produce The focus of the placement is on transfer fluids and there are minimal available of knowledge with the scientist developing therapies for patients. a novel scientific model which can be used to explore potential drug candidates for During this insightful meeting, patients shared their experiences of living Sjogren’s syndrome. with Sjogren’s Syndrome in order that academics and scientists from both This unique partnership allows both partners organisations could consider these for to develop their work in ways that would not drug development – a patient-focused be possible independently. The University, approach that GSK is now working to through its partnership with the NHS, embed across broader drug discovery opens up access to insights from patients and development. All participants found and a broader knowledge base, which the experience to be invaluable, with complements GSK’s research capabilities patients remarking that they felt hopeful that sharing their experiences would and expertise. The partnership with GSK improve the lives of Sjogren’s sufferers in allows University academics to translate their the future. research directly for patients’ benefit. The collaboration ultimately allows both partners, working together, to contribute to improving global healthcare. memproduksi cairan dan ada terapi minimal yang GSK telah tersedia untuk pasien. berkolaborasi dengan University of Selama pertemuan penuh wawasan ini, Birmingham (UoB) pasien berbagi pengalaman hidup mereka selama bertahun-tahun dengan Sindrom Sjogren agar akademisi di berbagai bidang dan ilmuwan dari keduanya termasuk kedokteran organisasi dapat mempertimbangkan hal gigi, dalam bisnis ini untuk pengembangan obat - Layanan Kesehatan pendekatan yang berfokus pada pasien Konsumen, dan yang kini sedang dilakukan GSK untuk pernapasan, menanamkan penemuan obat yang lebih dalam Farmasi. luas Interaksi antara kedua dan pengembangan. Semua peserta organisasi berkisar dari menemukan pengalaman itu sangat pemberian akademisi berharga, dengan klinis pasien mengatakan bahwa mereka layanan konsultasi, merasa berharap bahwa berbagi penelitian kolaboratif pengalaman mereka akan terjadi untuk membawa obat meningkatkan kehidupan penderita ke pasar, CASE Sjogren di masa depan. siswa untuk melakukan eksperimen khusus, dan uji klinis kegiatan untuk tahap akhir pengujian kandidat obat yang menjanjikan. Contoh lain di mana pendekatan baru untuk kolaborasi telah diterapkan adalah Dalam tiga tahun penunjukan ilmuwan pasca-doktoral, yang terakhir, luasnya dipekerjakan oleh GSK, yang akan kegiatan kolaboratif bekerja di laboratorium di Universitas telah berkembang, Birmingham selama dua tahun pertama khususnya di bidang dari tiga tahun posting mereka, kembali ke penyakit autoimun dan GSK untuk tahun ketiga. dalam hubungannya Fokus penempatan adalah pada transfer dengan GSK pengetahuan dengan ilmuwan Unit Obat mengembangkan model ilmiah baru yang Eksperimental. Di dapat digunakan untuk mengeksplorasi ruang inilah kandidat obat potensial untuk sindrom pendekatan paling Sjogren. baru untuk kolaborasi antara GSK dan Kemitraan unik ini memungkinkan kedua UoB telah muncul. mitra untuk mengembangkan pekerjaan Salah satu contohnya mereka dengan cara yang tidak mungkin Di sinilah akademisi dilakukan secara mandiri. Universitas, klinis dari Universitas melalui kemitraannya dengan NHS, datang bersama membuka akses ke wawasan dari pasien mereka dan basis pengetahuan yang lebih luas, kolaborator klinis dan yang melengkapi kemampuan dan ilmiah dari GSK untuk keahlian penelitian GSK. Kemitraan bertemu pasien yang dengan GSK memungkinkan akademisi telah Universitas menerjemahkan penelitian didiagnosis dengan mereka secara langsung untuk Sindrom Sjogren. Ini keuntungan pasien. Kolaborasi ini pada adalah kondisi akhirnya memungkinkan kedua mitra, autoimun jangka bekerja bersama, untuk berkontribusi panjang yang dalam meningkatkan layanan kesehatan memengaruhi bagian- global. bagian tubuh yang